注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Scopus BioPharma Inc是一家临床阶段的生物制药公司。该公司专注于免疫肿瘤学项目的开发。该公司的Duet平台依赖于一套双功能寡核苷酸的免疫肿瘤学,这些寡核苷酸可以激活肿瘤微环境中的抗原呈递细胞(APC),同时缓解肿瘤免疫抑制以启动T细胞介导的免疫反应。Duet平台由三个双功能寡核苷酸组成,它们由一个toll样受体9(TLR9)激动剂和一个信号转导和转录激活因子3(STAT3)抑制剂连接而成,包括CpG-STAT3siRNA(Duet-01)、CpG-STAT3ASO(Duet-02)和CpG-STAT3decoy(Duet-03)。该公司正在研发DUET-01,用于治疗复发或难治性B细胞非霍奇金淋巴瘤。它的生产线还包括MRI-1867,这是一种大麻素受体介导化合物,用于治疗系统性硬化症。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Joshua R. Lamstein | 51 | 2017 | Chairman |
George Kunos | - | 2017 | Member of Scientific Advisory Board |
Yossi Tam | - | 2018 | Member of Scientific Advisory Board |
David A. Buckel | 60 | 2020 | Independent Director |
Yair Levy | - | 2017 | Member of Scientific Advisory Board |
David Weild | 65 | 2020 | Independent Director |
Aharon Schwartz | 79 | 2018 | Member of Scientific Advisory Board |
Robert Spiera | - | 2017 | Member of Scientific Advisory Board |
Hua E. Yu | - | - | Member of Scientific Advisory Board |
Marcin Kortylewski | - | - | Member of Scientific Advisory Board |
Ira Scott Greenspan | 64 | 2017 | Senior Advisor & Director |
Robert J. Gibson | - | 2017 | Vice Chairman, Secretary & Treasurer |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核